2.50
Hdl Handle:
http://hdl.handle.net/10755/148734
Type:
Presentation
Title:
Current Treatment of Mitral Valve Disease
Abstract:
Current Treatment of Mitral Valve Disease
Conference Sponsor:Sigma Theta Tau International
Conference Year:2007
Author:McCluskey-Andre, Patti, RN, MSN, CCNS, ACNP-C
P.I. Institution Name:Hoag Memorial Hospital
Title:Cardiac Surgery Nurse Practitioner
[Leadership session research presentation] The mitral valve is a complex anatomical structure with mitral valve insufficiency (MVI) representing the second most common type of valve abnormality. The natural history of MVI has evolved in the past years with significant reduction in the incidence of rheumatic fever, longer life expectancy, along with increased recognition of the disorder. MVI continues to constitute a major health problem which will increase with the aging population. Newly released, 2006 American College of Cardiologists and American Heart Association (ACC/AHA) Guidelines for the Treatment of Valvular Disorders will assist medical professionals in gaining scientific background for practice application in changing treatment strategies. Evaluation, management and risk stratification of both asymptomatic and symptomatic patients will be discussed. MVI currently has multiple etiologies yet the most common, degenerative, is also the most successfully repaired. Why repair is becoming the gold standard whenever possible versus mechanical or tissue valve prostheses will be explored. Beyond the pathophysiology of the underlying disease, this session will cover the timing of surgery based on these new guidelines which advocate surgery, even in an asymptomatic patient. Case presentations incorporating diagnosis, diagnostic modalities, guideline recommendations along with operative techniques utilized will assist with an understanding of the implementation of evidence based practice in the care of mitral valve disease.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleCurrent Treatment of Mitral Valve Diseaseen_GB
dc.identifier.urihttp://hdl.handle.net/10755/148734-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Current Treatment of Mitral Valve Disease</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2007</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">McCluskey-Andre, Patti, RN, MSN, CCNS, ACNP-C</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Hoag Memorial Hospital</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Cardiac Surgery Nurse Practitioner</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">pandre@hoaghospital.org</td></tr><tr><td colspan="2" class="item-abstract">[Leadership session research presentation] The mitral valve is a complex anatomical structure with mitral valve insufficiency (MVI) representing the second most common type of valve abnormality. The natural history of MVI has evolved in the past years with significant reduction in the incidence of rheumatic fever, longer life expectancy, along with increased recognition of the disorder. MVI continues to constitute a major health problem which will increase with the aging population. Newly released, 2006 American College of Cardiologists and American Heart Association (ACC/AHA) Guidelines for the Treatment of Valvular Disorders will assist medical professionals in gaining scientific background for practice application in changing treatment strategies. Evaluation, management and risk stratification of both asymptomatic and symptomatic patients will be discussed. MVI currently has multiple etiologies yet the most common, degenerative, is also the most successfully repaired. Why repair is becoming the gold standard whenever possible versus mechanical or tissue valve prostheses will be explored. Beyond the pathophysiology of the underlying disease, this session will cover the timing of surgery based on these new guidelines which advocate surgery, even in an asymptomatic patient. Case presentations incorporating diagnosis, diagnostic modalities,&nbsp;guideline recommendations along with operative techniques utilized&nbsp;will assist with&nbsp;an understanding of the&nbsp;implementation of evidence based practice in the care of mitral valve disease.</td></tr></table>en_GB
dc.date.available2011-10-26T09:49:46Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T09:49:46Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.